Table 2 High-alert medications (n = 872) and administration routes were identified in the sub-sample (n = 743 medication error reports)

Parenteral nutrition preparations

IV

130 (14.9)

Hypertonic sodium chloride (greater than 0.9%)

IH ^a, IV, PO ^a

93 (10.7)

Potassium chloride concentrate

IV, PO ^a

66 (7.6)

Morphine

IV, PO

47 (5.4)

Heparin

IA, IV

43 (4.9)

Oxycodone

IM, IV, PO

42 (4.8)

Vincristine

IV

33 (3.8)

Fentanyl

IV, SL

28 (3.2)

Methotrexate

IV, IT, PO

27 (3.1)

Enoxaparin

SC

26 (3.0)

Cytarabine

IV, IT

23 (2.6)

Lipid emulsion

IV

21 (2.4)

Dopamine

IV

18 (2.1)

Milrinone

IV

18 (2.1)

Midazolam

IV, PO ^a, buccal

17 (1.9)

Liposomal amphotericin B

IV

16 (1.8)

Insulin Aspart

IV, SC

14 (1.6)

Hypertonic dextrose (20% or greater)

IV, PO ^a

14 (1.6)

Norepinephrine

IV

12 (1.4)

Epinephrine

IM, IV, local anaesthesia ^a

11 (1.3)

Insulin (human, biosynthetic)

IV

11 (1.3)

Propofol

IV

10 (1.1)

Doxorubicin

IV

9 (1.0)

Potassium phosphates concentrate

IV

9 (1.0)

Dexmedetomidine

IV, IN ^a

8 (0.9)

Mercaptopurine

PO

8 (0.9)

Pegaspargase

IM, IV

8 (0.9)

Tramadol

IV, PO

8 (0.9)

Amino-acid infusion

IV

7 (0.8)

Diazepam

IV, PO

7 (0.8)

Insulin Detemir

SC

6 (0.7)

Esketamine

IV, PO ^a

6 (0.7)

Levosimendan

IV

6 (0.7)

Lorazepam

IV, PO

6 (0.7)

Others ^b

various

64 (7.3)

Total

872 (100.0)